Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients.
Daniella KlebanerStephen Hamilton-DutoitThomas AhernAnatasha CrawfordThomas JakobsenDeirdre P Cronin-FentonPer DamkierEmiel JanssenAnders KjaersgaardAnne Gulbech OrdingHåvard SøilandHenrik Toft SørensenTimothy L LashYlva HellbergPublished in: PloS one (2017)
This study eliminates the previously suggested marker ApoD as a predictor of recurrence among tamoxifen-treated women.
Keyphrases
- newly diagnosed
- end stage renal disease
- ejection fraction
- poor prognosis
- chronic kidney disease
- breast cancer cells
- peritoneal dialysis
- positive breast cancer
- type diabetes
- metabolic syndrome
- adipose tissue
- binding protein
- breast cancer risk
- patient reported outcomes
- young adults
- pregnancy outcomes
- skeletal muscle
- patient reported